Fateh Hawal Lateef, Kareem Goran, Rezaeian Shahab, Moludi Jalal, Kamari Negin
Nursing Department, Kalar Technical College, Garmian Polytechnic University, Kalar 46021, Iraq.
Medical Laboratory Technology, Kalar Technical College, Garmian Polytechnic University, Kalar 46021, Iraq.
Clin Nutr Res. 2023 Oct 24;12(4):269-282. doi: 10.7762/cnr.2023.12.4.269. eCollection 2023 Oct.
Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19).
In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination.
Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group.
Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine.
ClinicalTrials.gov Identifier: NCT05851313.
维生素D参与先天性和适应性免疫系统以及炎症的生物学功能。我们旨在明确补充维生素D对2019冠状病毒病（COVID-19）检测呈阳性的受试者中，辉瑞/BioNTech疫苗接种的副作用以及针对严重急性呼吸综合征冠状病毒2的免疫球蛋白G反应的有效性。
在这项多中心随机临床试验中，498名COVID-19检测呈阳性的人被分为两组，在14至16周内接受维生素D胶囊或安慰剂（每日1粒，每粒含600 IU维生素D）。在第二次接种疫苗前后测量人体测量指标和生化参数。
补充14至16周后，干预组的免疫球蛋白G（IgG）增加了10.89±1.2 g/L，而对照组为8.89±1.3 g/L，两组之间差异显著（p = 0.001）。第二次接种疫苗后，补充组的25-羟基维生素D从最初的28.73±15.6 ng/mL显著增加至46.48±27.2 ng/mL，两者之间差异显著。体重指数（BMI）较高的人症状最多，根据BMI水平的副作用差异显著。补充8周后，肥胖参与者的IgG水平低于超重或正常受试者。干预组中，第二次接种时所有类型副作用的比例与第一次接种相比显著降低。
补充600 IU维生素D3可减少接种辉瑞/BioNTech疫苗的参与者的接种后副作用并提高IgG水平。
ClinicalTrials.gov标识符：NCT05851313。
